Concepedia

M.A. Insa Molla

MI

Statistics

Publications

2

Citations

39

H-Index

2

Active since

2022

Affiliations

Institut Català d'Oncologia(Current)

Hospital de Santa Maria

Hospital Clínico Universitario Virgen de la Victoria

AstraZeneca (United States)

Asan Medical Center

M.A. Insa Molla is an author at Institut Català d'Oncologia specializing in cancer pharmacology, oncology, and non-small cell lung cancer therapy.

Publications per year

2022–2022

2

Publications

2

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

M-J. Ahn, S-W. Kim, Laura Rodríguez et al. · Annals of Oncology · 2022 · 21 citations · Full text

, , +15

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.

Laurence Albigès, Sang‐We Kim, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2022 · 18 citations

, , +17

1–2 of 2